Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?

被引:0
|
作者
Ozkan Gungor
Mustafa Sevinc
Sena Ulu
Ismail Kocyigit
机构
[1] Kahramanmaras Sutcu Imam University,Nephrology Department, Medical Faculty
[2] Bakirkoy Dr. Sadi Konuk Education and Research Hospital,Nephrology Department
[3] Bahcesehir University,Nephrology Department, Medical Faculty
[4] Erciyes University,Nephrology Department, Medical Faculty
来源
International Urology and Nephrology | 2023年 / 55卷
关键词
Sarcopenia; Cardiovascular disease; Kidney patients; Muscle; Kidney;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiovascular disease (CVD) incidence is high in patients with chronic kidney disease (CKD) and is the most frequent cause of mortality in this population. Advanced age, hypertension, uremic toxins, endothelial dysfunction, atherosclerosis, hyperhomocysteinemia, oxidative stress, and inflammation are among the leading causes of increased CVD in advanced stages of CKD. Although defined as a decrease in muscle strength associated with aging, sarcopenia is also prevalent in CKD patients. Sarcopenia causes physical disability, low quality of life, and mortality. Regular exercise and nutritional supplementation may slow the progression of sarcopenia. Recent studies have shown that sarcopenia increases the risk of CVD and mortality in people with or without kidney disease. This review discusses the relationship between sarcopenia and CVD in light of the current literature.
引用
收藏
页码:1161 / 1171
页数:10
相关论文
共 50 条
  • [31] Chronic Kidney Disease Progression in Heart Failure What We Know, Don't Know, and Where to Next?
    Heerspink, Hiddo J. L.
    Neuen, Brendon L.
    Inker, Lesley A.
    JACC-HEART FAILURE, 2024, 12 (05) : 860 - 863
  • [32] Migraine and cardiovascular disease: what cardiologists should know
    Kalkman, Deborah N.
    Couturier, Emile G. M.
    El Bouziani, Abdelhak
    Dahdal, Jorge
    Neefs, Jolien
    Woudstra, Janneke
    Vogel, Birgit
    Trabattoni, Daniela
    MaassenVanDenBrink, Antoinette
    Mehran, Roxana
    de Winter, Robbert J.
    Appelman, Yolande
    EUROPEAN HEART JOURNAL, 2023, 44 (30) : 2815 - 2828
  • [33] Sarcopenia predicts cardiovascular disease in chronic kidney disease at advanced stage and associated risks
    Xuan, Yingli
    Pang, Shiqing
    Xie, Weizhen
    He, Ruibin
    Qin, Li
    Yuan, Jiangzi
    MEDICINE, 2023, 102 (45) : E35976
  • [34] GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
    Hayat, Javeria
    Shah, Nishant P.
    Agarwala, Anandita
    Khan, Muhammad Shahzeb
    Butler, Javed
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (08) : 341 - 351
  • [35] Electronic cigarettes and cardiovascular health: what do we know so far?
    MacDonald, Andrea
    Middlekauff, Holly R.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2019, 15 : 159 - 174
  • [36] Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?
    Levin, A
    Li, YC
    KIDNEY INTERNATIONAL, 2005, 68 (05) : 1973 - 1981
  • [37] Nephrotoxicity-What Do We Know and What Don't We Know?
    Skinner, Roderick
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (02) : 128 - 134
  • [38] Sarcopenia as a comorbidity of cardiovascular disease
    Sasaki, Ken-ichiro
    Fukumoto, Yoshihiro
    JOURNAL OF CARDIOLOGY, 2022, 79 (05) : 596 - 604
  • [39] Determinants of Sarcopenia in Elderly Patients with Chronic Kidney Disease
    Zhang, Jianmin
    Ran, Lei
    Zhang, Yapu
    Guo, Li
    Gong, Youlan
    Wu, Xiaoxi
    Wang, Lei
    IRANIAN JOURNAL OF KIDNEY DISEASES, 2023, 17 (04) : 191 - 198
  • [40] Diabetes, Cardiovascular Disease, and Cardiovascular Risk in Patients with Chronic Kidney Disease
    De Lima, Jose J. G.
    Gowdak, Luis Henrique W.
    David-Neto, Elias
    Bortolotto, Luiz A.
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (02) : 159 - 165